N/A N=57 Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase
Anhedonia
Primary: Change From Baseline to Week 15 in Neural Activation — 0.0075; -0.1059 Z-score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Cord Blood Transfusion In Preterm Neonates (CB-TrIP)
Premature Infant Disease · Transfusion Related Complication · Fetal Hemoglobin
Primary: Median Percentage of HbF at 32 Weeks of Post Menstrual Age — 93.2; 90.8; 58.0; 69.0 percentage of total Hb — p=<0.0001
Phase 4 N=19 A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
Juvenile Idiopathic Arthritis
Primary: Juvenile Arthritis Disease Activity Score (JADAS-71) — 0.60; 0.21; 0.00; 0.35 score on a scale
N/A N=22 Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
AIDS · AIDS Vaccines
Primary: Lymphocytes Viability Prediction (LOGIT Transformed) in CMI Samples Post-overnight Incubation Time Before Intracellular Cytokine Staining (ICS): "Intercept" Parameter…
Phase 4 N=74 Clinical Study of Generic and Brand Bupropion in Depression
Major Depressive Disorder
Primary: Area Under the Curve (AUC0-24) Ratio for Racemic Bupropion — .84; .88; .83; .89 percentage of Brand — p=<0.05
Phase 1 N=20 Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Anagrelide (SPD422) — 5.028; 3.180 nanogram per milliliter (ng/mL)
N/A N=135 Mindfulness-Based Cognitive Therapy for Suicide Prevention
Suicide
Primary: Suicide Event — 44; 92 count of events — p=.015
Phase 2 N=40 Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Hepatocellular Cancer
Primary: Time to Progression — 7.7 Months
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Phase 3 N=184 Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Patients With Bacterial Vaginosis at 3 Months — 15; 16 Participants
N/A N=288 Oral Health Educational Methods in Adolescence
Adolescent Behavior
Primary: Knowledge Score — 11; 13; 11; 13 score on a scale — p=0.001
Phase 2 N=45 PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
Lymphoma, Diffuse Large B-Cell
Primary: Overall Response Rate — 11.1 percentage of participants
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
N/A N=271 Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit
Sepsis · Procalcitonin · Antimicrobial Stewardship
Primary: Days of Antibiotic Therapy in the First 14 Days Following Randomization — 7.6; 6.6 days